• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Inogen Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/7/25 4:07:15 PM ET
    $INGN
    Industrial Specialties
    Health Care
    Get the next $INGN alert in real time by email
    8-K
    false0001294133Inogen Inc00012941332025-05-072025-05-07

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 07, 2025

     

     

    INOGEN, INC.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-36309

    33-0989359

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    859 Ward Drive

     

    Goleta, California

     

    93111

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (805) 562-0500

     

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, $0.001 par value

     

    INGN

     

    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 2.02. Results of Operations and Financial Condition.

    On May 7, 2025, Inogen, Inc. (the "Company") issued a press release reporting its financial results for the first quarter ended March 31, 2025. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

    The information set forth under this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such a filing.

    Item 9.01. Financial Statements and Exhibits.

    (d) Exhibits

     

    Exhibit

     

     Description

    99.1

    Press Release dated May 7, 2025.

    104

    The cover page of this Current Report on Form 8-K, formatted in Inline XBRL.


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

     

     

    INOGEN, INC.

     

     

     

     

    Date:

    May 7, 2025

    By:

    /s/ Michael Bourque

     

     

     

    Michael Bourque
    Executive Vice President
    Chief Financial Officer
    Treasurer
    (Principal Accounting and Financial Officer)

     


    Get the next $INGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $INGN

    DatePrice TargetRatingAnalyst
    2/15/2024Mkt Perform → Outperform
    William Blair
    8/8/2023$15.00 → $8.00Overweight → Neutral
    JP Morgan
    7/14/2023Buy → Hold
    Needham
    1/17/2023Outperform → Mkt Perform
    William Blair
    12/9/2021$47.00Hold → Buy
    Needham
    11/8/2021$70.00 → $40.00Hold
    Stifel
    11/5/2021$72.00 → $42.00Market Perform
    SVB Leerink
    11/2/2021$71.00 → $45.00Underweight → Neutral
    JP Morgan
    More analyst ratings

    $INGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, CFO & Treasurer Bourque Michael J. was granted 48,225 shares, converted options into 25,000 shares, covered exercise/tax liability with 28,579 shares and bought $24,960 worth of shares (3,000 units at $8.32) (SEC Form 4)

      4 - Inogen Inc (0001294133) (Issuer)

      3/4/25 6:42:36 PM ET
      $INGN
      Industrial Specialties
      Health Care
    • CEO and President Smith Kevin Raymond Merrill was granted 55,475 shares, converted options into 28,333 shares, covered exercise/tax liability with 39,797 shares and bought $100,245 worth of shares (11,709 units at $8.56), increasing direct ownership by 383% to 70,274 units (SEC Form 4)

      4 - Inogen Inc (0001294133) (Issuer)

      3/4/25 6:41:11 PM ET
      $INGN
      Industrial Specialties
      Health Care

    $INGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Inogen upgraded by William Blair

      William Blair upgraded Inogen from Mkt Perform to Outperform

      2/15/24 6:28:38 AM ET
      $INGN
      Industrial Specialties
      Health Care
    • Inogen downgraded by JP Morgan with a new price target

      JP Morgan downgraded Inogen from Overweight to Neutral and set a new price target of $8.00 from $15.00 previously

      8/8/23 6:37:35 AM ET
      $INGN
      Industrial Specialties
      Health Care
    • Inogen downgraded by Needham

      Needham downgraded Inogen from Buy to Hold

      7/14/23 7:51:45 AM ET
      $INGN
      Industrial Specialties
      Health Care

    $INGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Inogen Announces First Quarter 2025 Financial Results

      Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended March 31, 2025. "Inogen's strong first quarter financial results underscore our success in driving improved commercial and operational execution," said Kevin Smith, President and Chief Executive Officer. "We are making great progress and remain committed to positioning the company for sustainable growth and profitability, while creating value for all stakeholders." First Quarter 2025 Financial Results Total revenue in the first quarter of 2025 was $82.3 million, an increase of 5.5% from the prior-year p

      5/7/25 4:05:00 PM ET
      $INGN
      Industrial Specialties
      Health Care
    • Inogen to Report First Quarter 2025 Financial Results on May 7, 2025

      Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report first quarter 2025 financial results after the market closes on Wednesday, May 7, 2025. On the same day, the Company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET. Individuals interested in listening to the conference call may do so by dialing: US domestic callers (877) 841-3961 Non-US callers (201) 689-8589 Please reference Inogen to join the call. A live audio webcast and archived recording of the conference call will be available to all interested parties through the News / Events page on the Inogen Investo

      4/16/25 8:30:00 AM ET
      $INGN
      Industrial Specialties
      Health Care
    • Inogen To Present at 24th Annual Needham Virtual Healthcare Conference

      Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced management will participate in the 24th Annual Needham Virtual Healthcare Conference. Kevin Smith, President and Chief Executive Officer, and Michael Bourque, Chief Financial Officer, are scheduled to participate in a fireside chat on Tuesday, April 8, 2025, at 8:45 a.m. Eastern Time. A live audio webcast and archived recording of the presentation will be available to all interested parties through the News / Events page on the Inogen Investor Relations website. Inogen has used, and intends to continue to use, its Investor Relations website,

      3/20/25 8:30:00 AM ET
      $INGN
      Industrial Specialties
      Health Care

    $INGN
    SEC Filings

    See more
    • Inogen Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Inogen Inc (0001294133) (Filer)

      5/7/25 4:07:15 PM ET
      $INGN
      Industrial Specialties
      Health Care
    • SEC Form DEFA14A filed by Inogen Inc

      DEFA14A - Inogen Inc (0001294133) (Filer)

      3/27/25 8:03:28 AM ET
      $INGN
      Industrial Specialties
      Health Care
    • SEC Form DEF 14A filed by Inogen Inc

      DEF 14A - Inogen Inc (0001294133) (Filer)

      3/27/25 8:01:55 AM ET
      $INGN
      Industrial Specialties
      Health Care

    $INGN
    Leadership Updates

    Live Leadership Updates

    See more
    • Inogen Announces Appointment of Mira Kirti Sahney to Board of Directors and Retirement of Board Member Tom West

      Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Mira Kirti Sahney to Inogen's Board of Directors, effective January 31, 2025. The company also announced that Tom West, who has served as a director since April 2023, retired as a member of the Board of Directors, effective January 30, 2025. "We are thrilled to welcome Mira Sahney to the Inogen Board. Mira brings considerable management, technical, and operational experience in the medical device field to Inogen," said Elizabeth Mora, Chairperson of the Board. "Mira's appointment will further strengthen Inogen's Board with a

      2/3/25 4:00:00 PM ET
      $INGN
      $MDT
      $MYO
      Industrial Specialties
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • Sight Sciences Appoints MK Raheja as Executive Vice President, Research and Development and Brenton Taylor as Executive Vice President, Operations

      MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today the appointment of MK Raheja, Ph.D. as its Executive Vice President, Research and Development, and Brenton Taylor as its Executive Vice President, Operations, effective November 4, 2024. Sight Sciences also announced that Sam Park, its Chief Operating Officer, who oversaw both R&D and Operations, will be retiring from his role at the Company effective November 15, 2024, and will remain available as a con

      11/7/24 4:04:00 PM ET
      $INGN
      $SGHT
      Industrial Specialties
      Health Care
      Medical/Dental Instruments
    • Inogen Appoints Eric Pauls as Vice President of Sales, North America

      Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Eric Pauls as Vice President of Sales, North America, effective September 3, 2024. Mr. Pauls joins Inogen from RQM+, where he served as Chief Customer Officer. Kevin Smith, President and Chief Executive Officer of Inogen said, "We are excited to welcome Eric to the Inogen team. With over 20 years of experience driving growth and leading high-performing teams in the respiratory care business, his leadership will be instrumental as we expand our product offerings and solutions for patients with respiratory conditions in the Uni

      9/5/24 8:30:00 AM ET
      $INGN
      Industrial Specialties
      Health Care

    $INGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Inogen Inc

      SC 13G/A - Inogen Inc (0001294133) (Subject)

      11/14/24 11:12:09 AM ET
      $INGN
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed by Inogen Inc

      SC 13G - Inogen Inc (0001294133) (Subject)

      4/23/24 8:25:34 PM ET
      $INGN
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by Inogen Inc (Amendment)

      SC 13G/A - Inogen Inc (0001294133) (Subject)

      2/14/24 4:00:17 PM ET
      $INGN
      Industrial Specialties
      Health Care

    $INGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Commercial Officer Ramade Gregoire

      4 - Inogen Inc (0001294133) (Issuer)

      3/4/25 6:44:50 PM ET
      $INGN
      Industrial Specialties
      Health Care
    • EVP, Bus Dev, GC & Sec Smith Kevin P. was granted 1,186 shares (SEC Form 4)

      4 - Inogen Inc (0001294133) (Issuer)

      3/4/25 6:43:26 PM ET
      $INGN
      Industrial Specialties
      Health Care
    • EVP, CFO & Treasurer Bourque Michael J. was granted 48,225 shares, converted options into 25,000 shares, covered exercise/tax liability with 28,579 shares and bought $24,960 worth of shares (3,000 units at $8.32) (SEC Form 4)

      4 - Inogen Inc (0001294133) (Issuer)

      3/4/25 6:42:36 PM ET
      $INGN
      Industrial Specialties
      Health Care

    $INGN
    Financials

    Live finance-specific insights

    See more
    • Inogen Announces First Quarter 2025 Financial Results

      Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended March 31, 2025. "Inogen's strong first quarter financial results underscore our success in driving improved commercial and operational execution," said Kevin Smith, President and Chief Executive Officer. "We are making great progress and remain committed to positioning the company for sustainable growth and profitability, while creating value for all stakeholders." First Quarter 2025 Financial Results Total revenue in the first quarter of 2025 was $82.3 million, an increase of 5.5% from the prior-year p

      5/7/25 4:05:00 PM ET
      $INGN
      Industrial Specialties
      Health Care
    • Inogen to Report First Quarter 2025 Financial Results on May 7, 2025

      Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report first quarter 2025 financial results after the market closes on Wednesday, May 7, 2025. On the same day, the Company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET. Individuals interested in listening to the conference call may do so by dialing: US domestic callers (877) 841-3961 Non-US callers (201) 689-8589 Please reference Inogen to join the call. A live audio webcast and archived recording of the conference call will be available to all interested parties through the News / Events page on the Inogen Investo

      4/16/25 8:30:00 AM ET
      $INGN
      Industrial Specialties
      Health Care
    • Inogen Announces Fourth Quarter and Full Year 2024 Financial Results

      Results Reflect Strong Fourth Quarter 2024 Revenue Growth of 5.5%; Full-Year Revenue Growth of 6.4% Company Provides 2025 Growth Outlook Recently Announced Strategic Collaboration with Yuwell to Expand Product Portfolio, Global Reach Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter and the full year ended December 31, 2024. "2024 was a stellar year for Inogen. With our new leadership team in place, we returned the Company to growth, achieved significant milestones, and made meaningful steps towards profitability," said Kevin Smith, President and Ch

      2/25/25 4:05:00 PM ET
      $INGN
      Industrial Specialties
      Health Care